Guardian Pharmacy Services (GRDN) to Release Quarterly Earnings on Wednesday

Guardian Pharmacy Services (NYSE:GRDN) is projected to issue its Q4 2025 results after the market closes on Wednesday, March 11th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $390.0410 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:30 PM ET.

Guardian Pharmacy Services Stock Performance

NYSE:GRDN opened at $34.01 on Wednesday. The stock has a market capitalization of $2.15 billion, a PE ratio of 53.98 and a beta of 0.86. Guardian Pharmacy Services has a fifty-two week low of $17.78 and a fifty-two week high of $37.43. The company has a fifty day moving average of $31.47 and a two-hundred day moving average of $29.02.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its stake in Guardian Pharmacy Services by 26.5% during the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after purchasing an additional 345 shares during the period. California State Teachers Retirement System raised its position in shares of Guardian Pharmacy Services by 3.4% during the 4th quarter. California State Teachers Retirement System now owns 17,983 shares of the company’s stock valued at $541,000 after buying an additional 593 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its holdings in Guardian Pharmacy Services by 20.4% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,070 shares of the company’s stock valued at $183,000 after acquiring an additional 1,028 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Guardian Pharmacy Services by 13.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,885 shares of the company’s stock worth $358,000 after acquiring an additional 1,409 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Guardian Pharmacy Services by 31.1% during the third quarter. JPMorgan Chase & Co. now owns 7,899 shares of the company’s stock worth $207,000 after acquiring an additional 1,872 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a report on Monday, December 29th. Wall Street Zen upgraded Guardian Pharmacy Services from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 17th. Stephens raised their price objective on Guardian Pharmacy Services from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, January 14th. Finally, Truist Financial upped their target price on shares of Guardian Pharmacy Services from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.